Downregulation of HIF-1α inhibits the proliferation and invasion of non-small cell lung cancer NCI-H157 cells

Qian,Jialin; Bai,Hao; Gao,Zhiqiang; Dong,Yu; Pei,Jun; Ma,Meili; Han,Baohui

doi:10.3892/ol.2016.4150

Downregulation of HIF-1α inhibits the proliferation and invasion of non-small cell lung cancer NCI-H157 cells

Authors:
- Jialin Qian
- Hao Bai
- Zhiqiang Gao
- Yu Dong
- Jun Pei
- Meili Ma
- Baohui Han
View Affiliations

Affiliations: Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, P.R. China
Published online on: January 26, 2016 https://doi.org/10.3892/ol.2016.4150
Pages: 1738-1744
Copyright: © Qian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer, specifically non-small cell lung cancer (NSCLC), is the leading cause of cancer‑associated mortality in the world. In previous years, almost no significant advancements have been made towards the molecular characterization of NSCLC, which highlights the requirement for novel target genes. Hypoxia inducible factor‑1α (HIF‑1α) is known to be essential in tumorigenesis, as it regulates the expression of numerous factors that are involved in angiogenesis, cellular proliferation and apoptosis. However, no direct association between HIF‑1α and NSCLC treatment has previously been established. The aim of the present study was to characterize the effect of HIF‑1α on NSCLC and to explore the possible mechanism. Additionally, HIF‑1α small interfering (si)RNA and diamminedichloroplatinum (DDP) were used in combination to explore the combined effects on NSCLC cells. Lung carcinoma NCI‑H157 cells were treated with HIF‑1α small interfering (si)RNA, 5 µg/ml DDP or a combination of the two, and the proliferation, apoptosis and invasion ability of the cells were detected using a cell counting kit‑8 assay, Annexin V/propidium iodide staining and a Transwell assay, respectively. In addition, the protein levels of caspase‑3/9, anti‑apoptotic protein B‑cell lymphoma‑2 (Bcl‑2), vascular endothelial growth factor (VEGF), pigment epithelium‑derived factor (PEDF), phosphoinositide 3‑kinase (PI3K), phosphorylated (p‑)PI3K, protein kinase B (AKT), p‑AKT, extracellular signal‑regulated kinase (ERK) and p‑ERK were detected using western blot analysis. Similar to DPP treatment, HIF‑1α siRNA treatment may reduce cell proliferation and the invasiveness of tumor cells while promoting apoptosis. Additionally, HIF‑1α siRNA may increase the levels of the apoptotic proteins caspases 3 and 9 and inhibit the expression of Bcl‑2. These anti‑tumor effects may be acting through the VEGF/PEDF, PI3K/AKT and Raf/mitogen‑activated protein kinase kinase/ERK signaling pathways. The effects of HIF‑1α siRNA may be strengthened by DDP. The present data indicated that HIF‑1α siRNA is important in the inhibition of NSCLC cells. Additionally, the effects of HIF‑1α siRNA may be strengthened by DDP, which suggests that HIF‑1α siRNA may be combined with DDP for the treatment of tumors.

View Figures

View References

1	Fenton-Ambrose L and Kazerooni EA: Preventative care: Lung-cancer screens now worth the cost. Nature. 514:352014. View Article : Google Scholar : PubMed/NCBI
2	Ellis P: Minimally invasive thoracic surgery for early stage non-small cell lung cancer. BMJ. 349:g58492014. View Article : Google Scholar : PubMed/NCBI
3	Lococo F, Cesario A, Leuzzi G and Apolone G: Second primary on-small-cell lung cancer: Implications of the new adenocarcinoma classification in the challenging decision of the best surgical strategy. Eur J Cardiothorac Surg. 45:1115–1116. 2014. View Article : Google Scholar : PubMed/NCBI
4	Farías RO, Bortolussi S, Menéndez PR and González SJ: Exploring Boron Neutron Capture Therapy for non-small cell lung cancer. Phys Med. 30:888–897. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zhang Y, Ma M and Han B: GOLPH3 high expression predicts poor prognosis in patients with resected non-small cell lung cancer: An immunohistochemical analysis. Tumour Biol. 35:10833–10839. 2014. View Article : Google Scholar : PubMed/NCBI
6	Zhang J, Xu L, Yang Z, Lu H, Hu D, Li W, Zhang Z, Liu B and Ma S: MicroRNA-10b indicates a poor prognosis of non-small cell lung cancer and targets E-cadherin. Clin Transl Oncol. 17:209–214. 2015. View Article : Google Scholar : PubMed/NCBI
7	Zhang L, Qian J, Qiang Y, Huang H, Wang C, Li D and Xu B: Down-regulation of miR-4500 promoted non-small cell lung cancer growth. Cell Physiol Biochem. 34:1166–1174. 2014. View Article : Google Scholar : PubMed/NCBI
8	Zeuner A, Francescangeli F, Contavalli P, Zapparelli G, Apuzzo T, Eramo A, Baiocchi M, De Angelis ML, Biffoni M, Sette G, et al: Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. Cell Death Differ. 21:1877–1888. 2014. View Article : Google Scholar : PubMed/NCBI
9	Zhang C, Lan T, Hou J, Li J, Fang R, Yang Z, Zhang M, Liu J and Liu B: NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling. Oncotarget. 5:4392–4405. 2014. View Article : Google Scholar : PubMed/NCBI
10	Wu S, Cheng Z, Yu L, Song W and Tao Y: Expression of CD82/KAI1 and HIF-1α in non-small cell lung cancer and their relationship to vasculogenic mimicry. Zhongguo Fei Ai Za Zhi. 14:918–925. 2011.(In Chinese). PubMed/NCBI
11	Wang Q, Hu DF, Rui Y, Jiang AB, Liu ZL and Huang LN: Prognosis value of HIF-1α expression in patients with non-small cell lung cancer. Gene. 541:69–74. 2014. View Article : Google Scholar : PubMed/NCBI
12	Li Y, Qiu X, Zhang S, Zhang Q and Wang E: Hypoxia induced CCR7 expression via HIF-1α and HIF-2α correlates with migration and invasion in lung cancer cells. Cancer Biol Ther. 8:322–330. 2009. View Article : Google Scholar : PubMed/NCBI
13	Lv Y and Zhang P: Advances of HIF-1α and its role in lung cancer. Zhongguo Fei Ai Za Zhi. 12:147–151. 2009.(In Chinese). PubMed/NCBI
14	Jang BC: The fruit juice of Morinda citrifolia (noni) downregulates HIF-1α protein expression through inhibition of PKB, ERK-1/2, JNK-1 and S6 in manganese-stimulated A549 human lung cancer cells. Int J Mol Med. 29:499–504. 2012.PubMed/NCBI
15	Liang J, Qian Y, Xu D, Yin Q and Pan HJ: Serum tumor markers, hypoxia-inducible factor-1α HIF-1α and vascular endothelial growth factor, in patients with non- small cell lung cancer before and after intervention. Asian Pac J Cancer Prev. 14:3851–3854. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wang Q, Li LH, Gao GD, Wang G, Qu L, Li JG and Wang CM: HIF-1α up-regulates NDRG1 expression through binding to NDRG1 promoter, leading to proliferation of lung cancer A549 cells. Mol Biol Rep. 40:3723–3729. 2013. View Article : Google Scholar : PubMed/NCBI
17	Li L, Hu M, Yu JM, Yang GR, Guo HB and Gao Y: Correlations of 99 Tc m-HL91 SPECT hypoxia imaging with HIF-1α and VEGF expression in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi31. 669–673. 2009.(In Chinese).
18	Choi YJ, Rho JK, Lee SJ, Jang WS, Lee SS, Kim CH and Lee JC: HIF-1α modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 135:1047–1053. 2009. View Article : Google Scholar : PubMed/NCBI
19	Zuo S, Ji Y, Wang J and Guo J: Expression and clinical implication of HIF-1α and VEGF-C in non-small cell lung cancer. J Huazhong Univ Sci Technolog Med Sci. 28:674–676. 2008. View Article : Google Scholar : PubMed/NCBI
20	Li Y, Zhang Q, Jiang L, Qiu X and Wang E: Upregulation of the chemokine receptor CCR7 expression by HIF-1α and HIF-2α in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 11:724–728. 2008.(In Chinese). PubMed/NCBI
21	Ai B, Pan T, Zheng Z and Chen T: The relationship of expression of GLUT1, HIF-1α and the uptake of FDG in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 10:508–512. 2007.(In Chinese). PubMed/NCBI
22	Song X, Liu X, Chi W, Liu Y, Wei L, Wang X and Yu J: Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene. Cancer Chemother Pharmacol. 58:776–784. 2006. View Article : Google Scholar : PubMed/NCBI
23	Zhu C, Wang X, Zheng H, Liu T, Li Y, Sun C, Wang A and Zhao F: Expressions of EphB4 and HIF-1α in human lung cancer and their significances. Zhongguo Fei Ai Za Zhi. 8:99–102. 2005.PubMed/NCBI
24	Chang H, Shyu KG, Lee CC, Tsai SC, Wang BW, Lee Hsien Y and Lin S: GL331 inhibits HIF-1α expression in a lung cancer model. Biochem Biophys Res Commun. 302:95–100. 2003. View Article : Google Scholar : PubMed/NCBI
25	Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, et al: Treatment with HIF-1α antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol. 5:940–949. 2010. View Article : Google Scholar : PubMed/NCBI
26	Wan J, Ma J, Mei J and Shan G: The effects of HIF-1α on gene expression profiles of NCI-H446 human small cell lung cancer cells. J Exp Clin Cancer Res. 28:1502009. View Article : Google Scholar : PubMed/NCBI
27	Peng Z, Shan C and Wang H: Expression of VHL and HIF-1α and its clinical significance in the lung cancer tissue. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 34:331–334. 2009.(In Chinese). PubMed/NCBI
28	Naruke A, Azuma M, Takeuchi A, Ishido K, Katada C, Sasaki T, Higuchi K, Tanabe S, Saegusa M and Koizumi W: Comparison of site-specific gene expression levels in primary tumors and synchronous lymph node metastases in advanced gastric cancer. Gastric Cancer. 18:262–270. 2015. View Article : Google Scholar : PubMed/NCBI
29	Wang HL and Zhang ZL: Analysis of the relationship between ultrasound of breast cancer DOT-SDI and the expression of MVD, VEGF and HIF-1α. Cell Biochem Biophys. 70:205–208. 2014. View Article : Google Scholar : PubMed/NCBI
30	Zhou Z, Liu F, Zhang ZS, Shu F, Zheng Y, Fu L and Li LY: Human rhomboid family-1 suppresses oxygen-independent degradation of hypoxia-inducible factor-1α in breast cancer. Cancer Res. 74:2719–2730. 2014. View Article : Google Scholar : PubMed/NCBI
31	Anavi S, Hahn-Obercyger M, Madar Z and Tirosh O: Mechanism for HIF-1 activation by cholesterol under normoxia: A redox signaling pathway for liver damage. Free Radic Biol Med. 71:61–69. 2014. View Article : Google Scholar : PubMed/NCBI
32	Jo JR, Park YK and Jang BC: Short-term treatment with glucosamine hydrochloride specifically downregulates hypoxia-inducible factor-1α at the protein level in YD-8 human tongue cancer cells. Int J Oncol. 44:1699–1706. 2014.PubMed/NCBI
33	Chen L, Shi Y, Yuan J, Han Y, Qin R, Wu Q, Jia B, Wei B, Wei L, Dai G, et al: HIF-1 α overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients post-gastrectomy. PLoS One. 9:e906782014. View Article : Google Scholar : PubMed/NCBI
34	Clara CA, Marie SK, de Almeida JR, Wakamatsu A, Oba-Shinjo SM, Uno M, Neville M and Rosemberg S: Angiogenesis and expression of PDGF-C, VEGF, CD105 and HIF-1α in human glioblastoma. Neuropathology. 34:343–352. 2014.PubMed/NCBI
35	Liu H, Liu Z, Li J, Li Q, You C and Xu J: Relative quantitative expression of hypoxia-inducible factor 1α messenger ribonucleic acid in recurrent craniopharyngiomas. Neurol India. 62:53–56. 2014. View Article : Google Scholar : PubMed/NCBI
36	Green DR: Apoptotic pathways: Paper wraps stone blunts scissors. Cell. 102:1–4. 2000. View Article : Google Scholar : PubMed/NCBI
37	Reed JC: Double identity for proteins of the Bcl-2 family. Nature. 387:773–776. 1997. View Article : Google Scholar : PubMed/NCBI
38	De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2): S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
39	Heeg S, Hirt N, Queisser A, Schmieg H, Thaler M, Kunert H, Quante M, Goessel G, von Werder A, Harder J, et al: EGFR overexpression induces activation of telomerase via PI3K/AKT-mediated phosphorylation and transcriptional regulation through Hif1-α in a cellular model of oral-esophageal carcinogenesis. Cancer Sci. 102:351–360. 2011. View Article : Google Scholar : PubMed/NCBI
40	Richard DE, Berra E, Gothié E, Roux D and Pouysségur J: p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem. 274:32631–32637. 1999. View Article : Google Scholar : PubMed/NCBI
41	Minet E, Arnould T, Michel G, Roland I, Mottet D, Raes M, Remacle J and Michiels C: ERK activation upon hypoxia: Involvement in HIF-1 activation. FEBS Lett. 468:53–58. 2000. View Article : Google Scholar : PubMed/NCBI
42	Hur E, Chang KY, Lee E, Lee SK and Park H: Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1α. Mol Pharmacol. 59:1216–1224. 2001.PubMed/NCBI
43	van den Tweel ER, Kavelaars A, Lombardi MS, Nijboer CH, Groenendaal F, van Bel F and Heijnen CJ: Bilateral molecular changes in a neonatal rat model of unilateral hypoxic-ischemic brain damage. Pediatr Res. 59:434–439. 2006. View Article : Google Scholar : PubMed/NCBI
44	Zhang E, Feng X, Liu F, Zhang P, Liang J and Tang X: Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1α, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells. PLoS One. 9:e1034402014. View Article : Google Scholar : PubMed/NCBI
45	Yamagishi S, Matsui T, Nakamura K, Yoshida T, Shimizu K, Takegami Y, Shimizu T, Inoue H, Imaizumi T, et al: Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Microvasc Res. 71:222–226. 2006. View Article : Google Scholar : PubMed/NCBI